CN-121975936-A - Markers for FSGS diagnosis and treatment and uses thereof

Abstract

The invention relates to the technical field of biological medicine, in particular to a marker for diagnosing and treating FSGS and application thereof, aiming at the problem that a target biomarker for abnormal expression of FSGS is not screened in the prior art, five key target genes related to FSGS, namely JUN, PLK2, AKR1C3, PTGS2 and HSD11B2, are obtained by acquiring relevant data of the FSGS, analyzing the data and screening the data by machine learning, and the obtained key target genes are identified and verified, so that the five key target genes have strong indication efficiency on the FSGS and are ideal drug targets; and the active ingredients of the medicine are combined with key target genes through molecular docking technology, so that the combination affinity of the active ingredients of the Chinese medicine such as semen cuscutae and the like with target proteins is verified, and the application prospect of the Chinese medicine composition in the aspect of treating FSGS is further verified, and the diagnosis and treatment efficiency of the FSGS are forcefully promoted.

Inventors

• YIN MIN
• JIN ZHOUHUI

Assignees

• 上海市浦东新区人民医院

Dates

Publication Date

20260505

Application Date

20260128

Claims (9)

1. 1. A marker for diagnosis and treatment of FSGS, characterized in that the marker comprises at least one or more of JUN, PLK2, AKR1C3, PTGS2 and HSD11B 2.
2. 2. Use of an agent that detects expression of at least one gene of JUN, PLK2, AKR1C3, PTGS2 and HSD11B2 in the manufacture of a product for FSGS diagnosis.
3. 3. The method of claim 2, wherein the product comprises a primer, a detection reagent, a probe, a kit or a chip for identifying at least one gene selected from JUN, PLK2, AKR1C3, PTGS2 and HSD11B 2.
4. 4. The method of claim 3, wherein the detection reagent comprises an antibody that specifically detects at least one protein selected from the group consisting of JUN, PLK2, AKR1C3, PTGS2, and HSD11B 2.
5. 5. Use of a compound capable of specifically binding to at least one gene of JUN, PLK2, AKR1C3, PTGS2 and HSD11B2 in the manufacture of a medicament for the treatment of FSGS.
6. 6. The method according to claim 5, wherein the compound comprises an extract of at least one herb selected from cistanche, morinda officinalis, epimedium, astragalus, cuscuta chinensis, and hedyotis diffusa.
7. 7. A drug for treating FSGS, characterized in that the drug comprises a compound capable of specifically binding to at least one gene of JUN, PLK2, AKR1C3, PTGS2 and HSD11B 2.
8. 8. The medicine according to claim 7, wherein the active ingredients of the compound comprise extracts of at least one of cistanche, morinda officinalis, epimedium, astragalus, cuscuta chinensis and hedyotis diffusa, and pharmaceutically acceptable auxiliary materials.
9. 9. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises an oral preparation, an injection, a capsule, a tablet or a granule.

Description

Markers for FSGS diagnosis and treatment and uses thereof Technical Field The invention relates to the technical field of biological medicines, in particular to a marker for FSGS diagnosis and treatment and application thereof. Background Focal Segmental Glomerulosclerosis (FSGS) is an extremely complex kidney disease of great interest in clinical practice, which is one of the major etiologies leading to nephrotic syndrome and end-stage renal disease in adults and children. The remarkable characteristic of FSGS is glomerular scarring, which is a critical structure of kidney filtration, and this disease can seriously affect the growth and physical health of children patients, and also affect the quality of life of adult patients, and more worry, the condition of most patients can continuously worsen, eventually leading to end-stage renal disease, with poor prognosis. It is estimated that up to 50% of FSGS patients will progress to ESRD within 5-10 years after diagnosis, requiring reliance on kidney replacement therapy, placing a heavy burden on the patient's home and social medical system. At present, the standard treatment scheme aiming at FSGS mainly adopts corticosteroids and immunosuppressants clinically, but has different curative effects and obvious side effects, such as glucocorticoid which is used as a first-line treatment medicament, and part of primary FSGS patients respond to hormone treatment, but long-term and large-dose administration of the hormone can cause side effects such as central obesity, hyperglycemia, hypertension, osteoporosis, low immunity and easy infection, and the treatment compliance and the quality of life of the patients are seriously influenced. Furthermore, the pathogenesis of FSGS is extremely complex, and a plurality of links such as podocyte injury, genetic susceptibility, immune inflammatory response, hemodynamic changes and the like are involved. The existing immunosuppressants are mostly broad-spectrum medicines and are not developed aiming at specific pathogenic links of FSGS. Thus, existing immunosuppressants are very blind to the treatment of FSGS, which is the root cause of poor efficacy and frequent side effects. Therefore, the discovery of biomarkers that can directly and sensitively reflect FSGS-specific pathological activities is an urgent need in the field of FSGS medical diagnosis and treatment. In recent years, although high-throughput technologies such as genomics and transcriptomics bring new views for disease research and screening out some differential expression genes related to FSGS, most of the findings stay at the scientific research level and cannot be effectively converted into targeted therapeutic strategies with definite clinical application values. Meanwhile, the traditional Chinese medicine (such as semen cuscutae, astragalus and the like) accumulates a great deal of experience in clinical practice of kidney diseases, shows therapeutic advantages of multiple components, multiple targets and overall regulation, but has the defects of unclear action mechanism and unclear active components, is difficult to dock with the target theory of modern medicine, and greatly limits the acceptance, popularization and standardized application of the traditional Chinese medicine in the international range. If the target biomarker of the abnormal expression of the FSGS can be screened out, and a corresponding diagnosis kit and a corresponding therapeutic drug are developed, the screening, diagnosis and treatment of the FSGS in China can be promoted. Disclosure of Invention In view of the above problems, the present invention aims to provide a marker for FSGS diagnosis and treatment and application thereof, and in view of the problems that no targeted biomarker for FSGS abnormal expression has been screened in the prior art, the present invention obtains a key target gene group driving FSGS diagnosis and treatment progress through integrated bioinformatics and machine learning identification, and develops a corresponding diagnostic product and therapeutic drug based on the key target gene group. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: in one aspect, the invention provides markers for FSGS diagnosis and treatment, including at least one or more of JUN, PLK2, AKR1C3, PTGS2, and HSD11B 2. In another aspect, the invention provides the use of an agent that detects expression of at least one gene of JUN, PLK2, AKR1C3, PTGS2 and HSD11B2 in the manufacture of a product for FSGS diagnosis. Further, the product includes a primer, a detection reagent, a probe, a kit or a chip for recognizing at least one gene of JUN, PLK2, AKR1C3, PTGS2 and HSD11B 2. Further, the detection reagent comprises an antibody for specifically detecting at least one protein of JUN, PLK2, AKR1C3, PTGS2 and HSD11B 2. In another aspect, the invention also provides the use of a compound capable of specifically binding to at least one gene of